^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    thiotepa

    i
    Other names: DSP-1958
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, Alkylating agent
    Related drugs:
    2d
    HAP2HCT: TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, St. Jude Children's Research Hospital | N=140 --> 69 | Trial completion date: Aug 2025 --> Jun 2026
    Enrollment change • Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • WT1 (WT1 Transcription Factor) • CREBBP (CREB binding protein) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • HOXA9 (Homeobox A9) • NUP214 (Nucleoporin 214) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2) • KAT6A (Lysine Acetyltransferase 6A) • KDM5A (Lysine Demethylase 5A) • DEK (DEK Proto-Oncogene) • AFDN (Afadin, Adherens Junction Formation Factor) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    FLT3-ITD mutation
    |
    cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    4d
    CD34+ Transplants for Leukemia and Lymphoma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Guenther Koehne | Trial completion date: Sep 2032 --> Jun 2033 | Trial primary completion date: Sep 2032 --> Jun 2033
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
    4d
    The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    cytarabine • fludarabine IV • thiotepa • busulfan
    15d
    Immune Disorder HSCT Protocol (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Mar 2027 --> Apr 2026 | Trial primary completion date: Mar 2027 --> Apr 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab) • melphalan • fludarabine IV • thiotepa
    17d
    Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma (clinicaltrials.gov)
    P2, N=24, Recruiting, Zhejiang Cancer Hospital
    New P2 trial
    |
    Tyvyt (sintilimab) • Jaypirca (pirtobrutinib) • thiotepa
    25d
    CD45RA-depleted CD19-CAR T Cell Consolidation After TCR??+ T Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, St. Jude Children's Research Hospital | Initiation date: Dec 2025 --> May 2026
    Trial initiation date
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    1m
    Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma. (PubMed, Blood Adv)
    Conditioning was based on total body irradiation (TBI) in 30 patients and on chemotherapy in 27 patients, mainly with reduced-toxicity conditioning (RTC; Treosulfan, Fludarabine, and Thiotepa). Our data support the use of TBI-free conditioning and suggest improved outcomes with unrelated donors receiving ATLG prophylaxis. NCT00317408.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    fludarabine IV • thiotepa • Grafapex (treosulfan)
    1m
    A Phase II Clinical Study on the Efficacy and Safety of Combination Therapy with Thiotepa, Temozolomide, and Bevacizumab for Recurrent Glioblastoma (ChiCTR2500111976)
    P=N/A, N=60, Not yet recruiting, Cancer Hospital of Shandong First Medical University; Cancer Hospital of Shandong First Medical University
    New trial
    |
    Avastin (bevacizumab) • temozolomide • thiotepa
    1m
    A clinical study on the use of thiotepa in combination with semustine and cytarabine for conditioning of autologous hematopoietic stem cell transplantation in primary central nervous system lymphoma (ChiCTR2500111944)
    P=N/A, N=22, Not yet recruiting, Henan Provincial People's Hospital; Henan Provincial People's Hospita,medical
    New trial
    |
    CD34 (CD34 molecule)
    |
    cytarabine • thiotepa
    1m
    A prospective, multiple centers, single arm clinical study on the efficacy and safety of decitabine combined with improved TBF conditioning regimen in patients with myelodysplastic syndrome accompanied by myelofibrosis received Allogeneic hematopoietic stem cell transplantation. (ChiCTR2500114465)
    P2, N=54, Not yet recruiting, The First Affiliated Hospital of Zhejiang University, School of Medicine,; The First Affiliated Hospital of Zhejiang University, School of Medicine,
    New P2 trial
    |
    decitabine • fludarabine IV • thiotepa • busulfan
    2ms
    CALGB 51101: Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=113, Active, not recruiting, Alliance for Clinical Trials in Oncology
    Trial completion date
    |
    cytarabine • etoposide IV • carmustine • thiotepa
    2ms
    Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) (clinicaltrials.gov)
    P2, N=195, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carboplatin • cyclophosphamide • etoposide IV • vincristine • thiotepa